Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...
Encouraging results from three pipeline combination therapies ... The Massachusetts-based biotech already has two drugs approved for cystic fibrosis, Orkambi (lumacaftor+ivacaftor) and Kalydeco ...
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
Over 10 years we created a diverse pipeline to bring this vision ... and ongoing support from the Cystic Fibrosis Foundation and collaboration with Therapeutics Development Network, the Company ...
Enterprise Therapeutics has been awarded a block of funding from the Cystic Fibrosis Foundation to take a new, first-in-class drug for the genetic disorder through phase 2 testing. The Brighton ...
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
Over 10 years we created a diverse pipeline to bring this vision closer to reality with seven named product candidates across three therapeutic areas utilizing three novel, clinically-validated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback